Dengue is often misdiagnosed as malaria, and the result can be fatal for the patient. Learn more here about distribution, diagnosis, and treatment.

Dr. Maurie Markman considers the benefits of using drugs with relevant molecular targets as anticancer agents.

NCI budget cuts to 2 clinical trial programs endanger patients and cripple research, says Dr. Bruce Cheson, who calls for the feds to loosen their stranglehold on clinical trials.

Dr. David Kerr says 90% of new cancer drugs 'fail.' To reverse this rate, he advocates a novel model for drug development in which science is shared in open-access, industry-academic partnerships.

Dr. Nir Barzilai considers what research on the genetic makeup of very old healthy individuals might teach us about preventing age-related diseases.

ID specialists need the latest on emerging and reemerging infections, to provide care and to offer consultations. Paul G. Auwaerter, MD, offers the latest on 5 (old and new) viruses active now.

David Epstein, author of a book on sports genetics, considers what clinicians need to know about advances in sports and exercise genetics.

Liquid biopsy may detect cancer recurrence, changes in the tumor, and development of drug resistance -- eventually, says Dr. George Lundberg. But for now, patients and physicians should be wary.

Dr. Maurie Markman considers whether strategies known to reduce the risk for ovarian cancer might also be useful in women with a BRCA mutation.

Dr. Kathy Miller talks about John Cleland, who at age 23 with metastatic testis cancer enrolled in the first cisplatin-based trial in 1974, knowing that the investigational drug might offer him no benefit.